An update on the management of pancreatic neuroendocrine tumors.

摘要: Pancreatic neuroendocrine tumors (PNETs) are a rare and heterogeneous group of neoplasia differ in their clinical presentation, behavior, prognosis based on both histological features cancer stage at the time diagnosis. Although small-sized can be surgically resected, locally advanced metastatic confer poor prognosis. In addition, only limited treatment options available to latter patients with PNETs, such as hormonal analogs, cytotoxic agents, targeted therapy. selected patients, liver-directed therapies also used. As expected, clinicians taking care these challenged develop an effective comprehensive strategy for amid wide variety modalities. Targeted therapy PNETs is sunitinib everolimus. Presently, number studies ongoing assess efficacy newer agents alone combination previous PNETs. The authors reviewed current discussed emerging emphasized need identify biomarkers.